PhiChem Corp

PhiChem Corp maintains a debt-to-equity ratio of 0.22 and a current ratio of 2.18, indicating moderate leverage and strong short-term liquidity. The company's price-to-book ratio of 4.6 suggests the market values its equity at a premium to its book value. However, the company has negative net cash after subtracting total debt, signaling potential liquidity constraints. The company's return on equity of 7.95% and return on assets of 5.57% fall below the typical performance benchmarks for the specialty chemicals industry, indicating suboptimal capital efficiency. Gross margin of 36.0% (1159762680/3225652660) and operating margin of 14.6% (471125660/3225652660) suggest moderate profitability but room for improvement in cost control. Revenue concentration data is not available in the provided dataset, but the company's total assets of 7.01 billion CNY and total liabilities of 2.10 billion CNY indicate a relatively diversified capital base. The company's operating cash flow of 669.18 million CNY supports its capital structure, though free cash flow of 58.11 million CNY is relatively low for a company of its size. The company's capital expenditure of -493.90 million CNY indicates asset disposals or reductions in capital spending. With a price-to-earnings ratio of 57.78 and an enterprise value-to-EBITDA ratio of 50.17, the stock appears significantly overvalued relative to earnings and cash flow metrics. Analysts have assigned a mean price target of 31.82 CNY, which is 20.1% below the current market price of 39.79 CNY. The risk assessment identifies liquidity as a medium concern, with dilution risk rated as low. The company's negative net cash position after debt subtraction raises concerns about its ability to meet short-term obligations without external financing. No dilution sources are explicitly identified in the provided data, though the absence of diluted shares suggests no recent equity issuance. Recent analyst activity shows a mean recommendation of 2.00 (on a 1-5 scale), with one "buy" rating and no "strong buy" or "hold" ratings. The uniformity of price targets at 31.82 CNY suggests consensus among analysts about the stock's fair value.